|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AX25
|
|
gptkbp:CASNumber
|
1985606-14-1
|
|
gptkbp:chemicalFormula
|
C27H23F2N3O7
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:developer
|
gptkb:Shionogi
|
|
gptkbp:eliminationHalfLife
|
79.1 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
granules
|
|
gptkbp:genericName
|
gptkb:baloxavir_marboxil
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xofluza
|
|
gptkbp:indication
|
post-exposure prophylaxis of influenza
treatment of acute uncomplicated influenza
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
cap-dependent endonuclease inhibitor
|
|
gptkbp:metabolism
|
liver (UGT1A3, CYP3A4)
|
|
gptkbp:pregnancyCategory
|
not assigned (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:sinusitis
bronchitis
nausea
diarrhea
headache
|
|
gptkbp:usedFor
|
influenza
|
|
gptkbp:bfsParent
|
gptkb:baloxavir_marboxil
gptkb:Roche
gptkb:Shionogi
|
|
gptkbp:bfsLayer
|
6
|